generates NO after uptake by the islet cells, suggesting that this is part of the toxic action of streptozotocin [ 111.
generates NO after uptake by the islet cells, suggesting that this is part of the toxic action of streptozotocin [ 111.
It has also been found that endothelial lining cells can express iNOS after cytokine challenge [12] . As islets are densely capillarized and thus contain numerous endothelial cells, we searched for iNOS expression in these cells. We established pure islet capillary endothelial cell cultures and found that these cells are indeed capable of generating excessive amounts of NO after appropriate cytokine challenge [ 131. Recent results from our laboratory show that after activation these endothelial cells are indeed capable of effectively lysing syngeneic islet cells.
In conclusion, evidence is slowly accumulating of a decisive role of NO production by macrophages and endothelial cells and eventually also other cells in local inflammatory destructive processes. Thus inducible synthesis of nitric oxide serves complex biological functions, as reviewed recently [ 141, and also contributes to autoiommune tissue destruction at inflamed sites.
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1 Hanenberg, H., Kolb-Bachofen, V., Kantwerk progression and proliferation ( [ 11, 121) . Here I review the discovery of TOR, our current understanding of the yeast TOR signalling pathway, and how it may mediate G1 progression and proliferation by controlling cell growth. The immunosuppressants cyclosporin A (CsA), FK506 and rapamycin suppress the human immune system by blocking intermediate steps in T-cell signal transduction pathways that are activated in response to antigen presentation. To determine whether these drugs could be used as probes of signalling pathways in yeast, we examined whether they affect growth and proliferation of yeast cells as they do T cells [1, 13] .
We found that CsA had no effect on our lab strains although it is toxic to lab strains of others [14] . However, FK506 is mildly toxic and rapamycin is extremely toxic to our lab strains [1, 13] . We thus focused on rapamycin as a potential probe of signalling pathways in yeast cells. The additional finding that rapamycin prevents proliferation of yeast and T cells by arresting both cell types in the G1 phase of the cell cycle was an indication that the underlying mode of action of the drug was conserved and therefore also involved blocking intermediate steps of signal transduction in yeast [ 1,111.
T o study rapamycin action, we identified a yeast FKBP [13] . FKBP had previously been identified in mammalian cells in vitro as a receptor of the structurally related FK506 and rapamycin, and as a proline isomerase (proline rotamase) [15, 16] . Yeast FKBP was purified to homogeneity by affinity chromatography with an FK506 column and shown to have proline isomerase activity. The protein was partly sequenced and several pools of degenerate oligonucleotides were synthesized. With appropriate pairs of oligonucleotides and PCR, specific chromosomal fragments of expected sizes were amplified. The PCR-derived fragments were used as probes to isolate the FKBP gene from a yeast genomic library. The DNA sequence of the isolated gene was determined and found to match that predicted from the protein sequence. The predicted amino acid sequence of yeast FKBP was also 54% identical to that of human FKBP, providing a further indication that the mode of action of rapamycin is conserved between yeast and human cells. Disruption of the FKBP gene (FPR1, for FK506-binding proline rotamase) and the previously isolated cyclophilin (also an immunophilin and proline isomerase) gene (CPR1, for CsA-binding proline rotamase) revealed that neither is essential for growth (the fir1 cprl double mutant is viable). Additional FKBPs and cyclophilins were subsequently discovered and cloned, and again single and multiple disruptions were constructed without loss of viability [ 1 1, .
The finding that FKBP disruptions are not lethal, even in combination with cyclophilin disruptions, was puzzling because FKBP was believed to be the binding proteinltarget in vivo for the toxic rapamycin and FK506. This finding and the observation by others [15, 20] that some FK506 analogues are able to bind and inhibit FKBP proline isomerase activity but are not immunosuppressive led to the currently accepted model of immunosuppressive drug action. A drug-immunophilin complex gains a new toxic activity that poisons another target molecule. An important observation in establishing this model was that an FPRl disruption is not only nonlethal but also confers resistance to FK506 and rapamycin [1, 13, 21, 22] .
T o identify the target of the FKBP-rapamycin complex, rapamycin-resistant mutants were selected [ 1,231. As expected, fprl mutants were recovered but also mutants altered in two novel genes, TORl and TOR2 (for target of rapamycin), were obtained. The TORl and TOR2 genes were cloned, based on a dominant rapamycin-resistance phenotype of the TORI-I and TOR2-I mutant alleles, and sequenced [2,3,23]. The predicted TORl and TOR2 proteins are both 282 kDa in size and 67% identical. The early finding that disruption of TORl and TOR2 in combination causes a G1 arrest, as does exposure to rapamycin, suggested that TORl and TOR2 are the targets of FKBP-rapamycin and that the FKBP-rapamycin complex inhibits TOR activity [2,3]. More recently, it has been demonstrated that the FKBP-rapamycin complex indeed binds directly to TOR and this binding is eliminated by the mutations in TORl and TOR2 that confer rapamycin resistance [24, 25] .
The extremely large and highly homologous TORl and TOR2 proteins (and mTOR) are structurally related to known or presumed phosphatidylinositol kinases [2] (Figure 1 ).
These include the p l l 0 catalytic subunit (a, p and y isotypes) of mammalian PI 3-kinase [26-281, the yeast PI 3-kinase VPS34 [29] , human PI 4-kinase PI4Ka [30] , the yeast PI 4-kinases PIKl [31, 32] and STT4 [33] , and the putative yeast PI kinase MEClIESRl [34] . PI kinases produce PI-derived second messengers. PI 3-kinase phosphorylates phosphoinositides at the 3'-hydroxyl group of the inositol ring. In mammalian cells, the enzyme is associated with activated receptor and non-receptor tyrosine kinases and probably plays a key role in signal transduction and cell cycle activation [35] . The yeast VPS34 associates with a serinelthreonine protein kinase and is required for vacuolar protein sorting [36] . PI 4-kinases catalyse the first committed step in the production of the second messenger inositol 1,4,5-trisphosphate. T h e similarity to PI kinases suggest that the TORS are PI kinases, although this has not been demonstrated directly. T h e G1 arrest conferred by a TOR deficiency is consistent with a role as a PI kinase, but again does not distinguish . Thus we believe that TORl and TOR2 are the same type of PI kinase and that this PI kinase activity is inhibited by FKBP-rapamycin.
Although structurally and functionally similar, TORl and TOR2 are not identical [2,3]. Disruption of TORl and TOR2 in combination causes G1 arrest; disruption of TOR2 alone is lethal but does not cause a G1 arrest; and disruption of TORl alone has little or no effect. Thus, because loss of TOR2 cannot be completely compensated for by TORl (even when present in increased dosage), at least TOR2 appears to have two functions. One function is presumably a TOR1-like, essential, cell-cycle function whereas the second TOR2 function is TOE-unique, also essential, and not necessarily related to the cell cycle (Figure 2 ). The findings that the lipid kinase domains of TORl and TOR2 are interchangeable and that rapamycin inhibits both TORl and TOR2 to confer a G1 arrest suggest that the shared cell-cycle function of TORl and TOR2 most probably involves rapamycin-sensitive PI kinase activity [3] . TOR2 as a PI kinase may also have a role in membrane traffic (in addition to a role in cell-cycle activation) similar to that of the yeast PI 3-kinase VPS34, in agreement with the observation that the lipid kinase domain of TOR2 is required for both functions of TOR2 [25] . Alternatively, the second function of the large TOR2 protein could be independent of PI kinase activity. We expect that the regions of TORl and TOR2 other than the lipid kinase domains (including the promoters) are responsible for the functional differ- Volume 24 Pharmacological Targets in the Immune Response cells enter upon starvation [37] , and suggest that
The two functions of TOR2 TOR2 has two fundions. One fundion is essential, TORZ-unique and unrelated to the cell cycle (GI). The second function is also essential. redundant with TORI (TORI -like), and required for GI progression.
non-G1 function G1 function (easentlai) (essential)
ence(s) between TORl and TOR2 [3, 25] . Although the two functions of TOR2 remain to be unravelled, TORl and TOR2 seem to be functionally overlapping PI kinases required to activate the cell cycle. If TOR2 has a second, essential function that TORl is unable to perform, why is a mutation of TORl (TORI-I) sufficient to confer rapamycin resistance? One possibility is that the TOE-unique function is not rapamycin sensitive [25] . Another possibility is that the TOR unique function is normally sensitive, but TORl and TOR2 form homo-and heterodimers and one rapamycin-insensitive TORl subunit is sufficient to allow a heterodimer to escape binding or inhibition by FKBP-rapamycin. According to this latter case, the heterodimer and the TOR2 homodimer would perform the TOR2-unique function whereas the shared function would be performed also by the heterodimer and by the TORl homodimer. Non-allelic non-complementation between TORl and TOR2 alleles suggest that at least TORl and TOR2 do indeed interact Further examination of rapamycin-treated or TOR-depleted cells revealed that loss of TOR function causes yeast cells to arrest in early G I , undergo a severe reduction in protein synthesis, accumulate the storage carbohydrate glycogen, acquire thermotolerance, enlarge the vacuole, and transcriptionally induce specific genes while repressing others. These phenotypes collectively define the stationary phase, or GO, which yeast [ll.
TOR is normally required to sense the availability of nutrients. TOR may signal a growth response in the presence of nutrients, whereas the lack of such a signal in the absence of nutrients would result in a growth arrest (GO) Loss of TOR function causes a general inhibition of protein synthesis. T h e decrease in protein synthesis is severe (down to approx. 10% of normal levels), immediate (it is the first effect seen upon rapamycin treatment), and at the level of translation initiation. The immediacy of the protein synthesis defect and the fact that a reduction in translation initiation causes an early G1 arrest in yeast [38, 39] suggested that the block in translation is a direct consequence of loss of TOR and the cause of the G1 arrest. Accordingly, the primary role of TOR would be to control general protein synthesis, and the role of TOR in cell-cycle control would be just a secondary consequence of this greater role in general growth control. Protein synthesis is required throughout the cell cycle but is most limiting in G1 [40] . Thus TOR may simply control the cell cycle by controlling translation of unstable proteins required for G1 progression, the best, if not the only, candidates for such proteins being the G1 cyclins. T o test this model we altered the translational regulation of the G1 cyclin CLN3 such that it would be expressed independently of TOR, and then asked whether this would suppress the rapamycin-induced G1 arrest [12] . T o express CLN3 in rapamycintreated cells, a hybrid gene was constructed in which the open reading frame of the CLN3 gene was fused to the promoter and 5' untranslated region of the UBI4 gene. The UBI4 gene, encoding ubiquitin, was chosen because it is both transcribed and translated in GO. This single alteration, allowing translation initiation of a G1 cyclin in rapamycin-treated cells, was sufficient to suppress the rapamycin-induced G1 arrest. The rapamycin-treated cells containing the UBI4-CLN3 fusion still arrested growth, because of the general protein synthesis defect, but arrested randomly in the cell cycle. This result argues that TOR'S primary role is indeed to control general growth (general protein synthesis) rather than to control the cell cycle machinery specifically. Furthermore, because TOR appears to mediate G1 progression through translation initiation, the shared G1 function of TORl and TOR2 must be related to the control [121.
of translation initiation. It remains to be determined whether the TOR2-unique function is also involved in translation initiation.
The model
Rapamycin treatment or TOR depletion causes a starvation response, including an early G1 arrest and a severe reduction in translation initiation. The G1 arrest phenotype can be suppressed by altering the translational control of a G1 cyclin. Based on these observations, we propose the following speculative model for the role of the shared function of TOR1 and TOR2 in cell-cycle control (Figure 3 ) [12] . In response to nutrient availability, TOR stimulates translation initiation by activating the general initiation factor eIF-4E (see below). This, in turn, promotes translation of the G1 cyclins (among other proteins), which drives cells through G1 and into S-phase. In the converse situation, the absence of nutrients causes inactivation of TOR, which leads to loss of the unstable G1 cyclins, and an early G1 arrest and entry into GO. Thus the TOR signalling pathway constitutes a checkpoint that prevents G1 progression and growth in the absence of nutrients. It is important to emphasize that
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Figure 3
Model of TOR signalling pathway controlling growth FKBP-rapamycin binds TOR directly [24, 25] . See text for further details. Abbreviations: R, rapamycin; TOR, TORI and TOR2. Cell growth G1 progresslon TOR is required for general translation and that the role of TOR in cell-cycle control is therefore not specific to the cell-cycle machinery, but is part of a greater role in general growth control.
T h e above model proposes that the TOR pathway controls translation initiation through the initiation factor eIF-4E (or an associated subunit). eIF-4E is the cap-binding subunit of the eIf-4F complex, which also contains eIF-4A, an RNA helicase, and eIF-4y, a protein of unknown function. eIF-4F binds to the 5' cap structure of mRNA and promotes the unwinding of 5' secondary structure, facilitating binding of the 43 S ribosomal preinitiation complex to the mRNA. Several observations suggest that TOR could control eIF-4E. First, CDC33 (encodes eIF-4E) and TOR mutations both cause a general defect in translation initiation and an early G1 arrest [ 12, 39, 41] . Secondly, UBI4 is synthesized in a CDC33 mutant and may therefore be eIF-4E independent [39] . Thirdly, in mammalian cells, activation of protein synthesis in response to growth factors is rapamycin-sensitive and controlled through eIF-4E; phosphorylation and release of the eIF-4E-inhibiting factor 4E-BP1/ PHAS-I in response to growth factors are inhibited by rapamycin [lo] . Thus the block in translation initiation caused by loss of TOR function in yeast may be due to a lack of eIF-4E activation.
Our results suggest that the TOR pathway is a control mechanism that activates synthesis of the cell-cycle machinery and G1 progression when nutrients are sufficient. Such a mechanism is contrary to prevailing views on the regulation of early G1 in yeast, according to which there is no special mechanism linking nutrient availability, protein syntheiss and the cell-cycle machinery; G1 progression is a simple and indirect consequence of nutrients as an energy source and building material allowing a high rate of G1 cyclin and CDC28 synthesis [38, 42] . However, this model was based solely on a lack of evidence that G1 cyclins or CDC28 are directly affected by nutrient status [42] . Thus, yeast cells could 'consciously' control G1 progression in response to nutrients as a signal, via the TOR signalling pathway.
